Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 References  














Abetimus






فارسی
Polski
Tiếng Vit
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Abetimus sodium
Clinical data
Trade namesRiquent
ATC code
Identifiers
CAS Number
PubChem SID
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC1632H1944N610Na156O970P156S4
Molar mass54171.35 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Abetimus (trade name Riquent) is an immunosuppressant.[1] It is a synthetic biological called a tolerogen. It is made of four double-stranded oligodeoxyribonucleotides that are attached to a carrier platform and are designed to block specific B-cell anti double stranded DNA antibodies.[2] It may also complex anti dsDNA antibodies together, therefore disabling them. This way abetimus was supposed to help treat systemic lupus erythematosus and specifically lupus nephritis.

It was developed by La Jolla Pharmaceutical, who applied for marketing authorisations in the mid-2000s, but the drug was never marketed in the US or in Europe.[3][4]

References

[edit]
  1. ^ "Abetimus: Abetimus sodium, LJP 394". BioDrugs. 17 (3). Springer Nature Switzerland AG: 212–5. 2003. doi:10.2165/00063030-200317030-00009. PMID 12749759. S2CID 19896886.
  • ^ Wallace DJ (January 2001). "Clinical and pharmacological experience with LJP-394". Expert Opinion on Investigational Drugs. 10 (1). Informa: 111–7. doi:10.1517/13543784.10.1.111. PMID 11116284. S2CID 43518002.
  • ^ "Riquent Approval Status". Drugs.com. Retrieved 7 January 2017.
  • ^ "Riquent". European Medicines Agency. Retrieved 7 January 2017.
  • t
  • e

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=Abetimus&oldid=1135139837"

    Categories: 
    Immunosuppressants
    Antineoplastic and immunomodulating drug stubs
    Hidden categories: 
    Articles with short description
    Short description matches Wikidata
    Articles with changed CASNo identifier
    Chemicals that do not have a ChemSpider ID assigned
    Articles with changed KEGG identifier
    Infobox drug articles with non-default infobox title
    Articles without EBI source
    Chemical pages without DrugBank identifier
    Articles without InChI source
    Drugs with no legal status
    Drugboxes which contain changes to verified fields
    Drugboxes which contain changes to watched fields
    All stub articles
     



    This page was last edited on 22 January 2023, at 21:49 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki